Michael J. Reardon, MD: Long-Term TAVR Plans
Low Risk TAVR: What the Data Tells Us (Michael J. Reardon, MD) March 26, 2020Подробнее
TAVR: Optimizing the Choice of Prosthesis and Patient (MICHAEL J. REARDON, MD)Подробнее
TAVR and Valve-in-Valve (Michael Reardon, MD)Подробнее
TAVR is an All Comers Therapy - Michael Reardon, MDПодробнее
TAVR Horizons: Partner II, SurTAVI and Beyond (Michael J. Reardon, MD) April 30, 2016Подробнее
TAVR-Device Selection & Expanding Indications/Percutaneous Alt. Access (Michael J. Reardon, MD)Подробнее
How I Teach TAVR (Ross M. Reul, MD, and Michael J. Reardon, MD)Подробнее
Transcatheter Aortic Valve Replacement: Will Surgical AVR Disappear? (Michael Reardon, MD)Подробнее
Michael J. Reardon, MD: The TAVR Study for Low-Risk MortalityПодробнее
Michael J Reardon, MD - TAVR in Asymptomatic or Moderate ASПодробнее
TMVR - Hope or Hype (Michael J. Reardon, MD)Подробнее
Disruptive Innovation: TAVR 20 Years Later | April 4Подробнее
TAVR Data for the Surgeon (Michael Reardon, MD)Подробнее
Cerebral Embolization During Protected TAVR(Lumsden MD, Reardon MD, Kleiman MD, Sinha MD, Garami MD)Подробнее
TAVR (Michael J. Reardon, MD) - April 6th, 2017 Re-Evolution SummitПодробнее
Which Low-Risk Patients Should Receive TAVR?Подробнее
Self-Expanding Transcatheter or Surgical AVR in severe AS Pts at Low Surgical RiskПодробнее
Michael J Reardon, MD on durability of TAVR in patients with aortic stenosis with Chadi Alraies, MDПодробнее
The Treatment of Aortic Valve Disease in 2020, A Surgeon’s Perspective (Michael J. Reardon, MD)Подробнее
TAVR Valves That Are Here and Valves That Are Coming (Michael Reardon, MD)Подробнее